Policy Notices

• RESCINDED - Flexibilities for Assured Institutions for Activities of Institutional Animal Care and Use Committees (IACUCs) Due to COVID-19
  (NOT-OD-20-088)
  National Institutes of Health
  

General Notices

• Notice of NIBIB's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"
  (NOT-EB-20-003)
  National Institute of Biomedical Imaging and Bioengineering
  

• Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19
  (NOT-OD-20-087)
  National Institutes of Health
  

• RESCINDED - Notice of Information: Leveraging STRIDES for Cloud Computing Activities in Common Fund Awards
  (NOT-RM-20-009)
  Office of Strategic Coordination (Common Fund)
  

• Request for Information: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Strategic Plan
  (NOT-DK-20-015)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

Notice of Changes to Funding Opportunities

• Notice to Extend the Expiration Date for PAR-17-214 "Limited Competition: Analysis of Data from NIA's Alzheimer's Disease Sequencing Project Follow-Up Study (U01)"
  (NOT-AG-20-021)
  National Institute on Aging
  

• Notice of Clarification of Additional Considerations listed in NIAID RFA-AI-20-009, Three-Dimensional (3D) Human Biomimetics for Infectious Diseases (U19 Clinical Trial Not Allowed)
  (NOT-AI-20-039)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Participation of the NIAMS in PAR-19-333, SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Not Allowed.
  (NOT-AR-20-017)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  

• Notice to Extend the Submission Period to the National Cancer Institute (NCI) for PA-18-592, Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed)
  (NOT-CA-20-040)
  National Cancer Institute
  

• Notice of correction to PAR-19-370 NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)
  (NOT-DE-20-017)
  National Institute of Dental and Craniofacial Research
  

• Notice of NIDCR Participation in PAR-19-343 "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)"
  (NOT-DE-20-018)
  National Institute of Dental and Craniofacial Research
  

• Notice of Change to Cover Letter Instructions for RFA-DK-20-502, Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (BRC) (Collaborative U01 Clinical Trial Required)
  (NOT-DK-20-017)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Expiration of RFA-HL-20-014 "Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed)"
  (NOT-HL-20-756)
  National Heart, Lung, and Blood Institute
  

• Notice of Change to Award Budget for PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grant Applications
  (NOT-OD-20-080)
  National Institutes of Health
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional)
  (NOT-DA-20-044)
  National Institute on Drug Abuse
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)
  (NOT-DA-20-045)
  National Institute on Drug Abuse
  

Notices of Special Interest

• Notice of Special Interest: Administrative Supplement Opportunity to Stimulate or Strengthen Global Cancer Health Disparities Research
  (NOT-CA-20-032)
  National Cancer Institute
  

• Notice of Special Interest: Alcohol and Cancer Control
  (NOT-CA-20-034)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Availability of Administrative Supplements for Research in Geographically Underserved Areas
  (NOT-CA-20-035)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Administrative Supplements for Development of Risk-Stratified Cancer Survivorship Care Algorithms
  (NOT-CA-20-038)
  National Cancer Institute
  

• Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
  (NOT-DA-20-047)
  National Institute on Drug Abuse
  

• Notice of Special Interest (NOSI): Availability of Administrative Supplements for Providing Research Experiences in Genomic Research for Genetic Counselors
  (NOT-HG-20-028)
  National Human Genome Research Institute
  

• RESCINDED - Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
  (NOT-HL-20-757)
  National Heart, Lung, and Blood Institute
  

• Notice of Special Interest (NOSI): Administrative Supplements for Minor Alterations or Renovations to Advance Ongoing HIV/AIDS Research Projects funded by the Research Centers in Minority Institutions (RCMI) Program
  (NOT-MD-20-013)
  National Institute on Minority Health and Health Disparities
  

• Notice of Special Interest to Highlight High Priority Opportunities for Intervention Development Research in Geriatric Mental Health
  (NOT-MH-20-027)
  National Institute of Mental Health
  

• Notice of Special Interest (NOSI): Competitive Revisions for Firearms Injury and Mortality Prevention Research
  (NOT-OD-20-089)
  Office of Behavioral and Social Sciences Research
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  Office of Disease Prevention
  Office of Research on Women's Health
  

Funding Opportunities

• Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 Clinical Trial Optional)
  (PA-20-141)
  National Institute of Mental Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below
  
  

• Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)
  (PA-20-142)
  National Institutes of Health
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute of Nursing Research
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): Standard dates apply All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Center of Excellence for Research on Complementary and Integrative Health (P01,Clinical Trial Optional)
  (PAR-20-138)
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is May 25, 2020. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)
  (PAR-20-140)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Standard dates apply.
  
  

• Firearm Injury and Mortality Prevention Research (R61 Clinical Trial Optional)
  (PAR-20-143)
  Office of Behavioral and Social Sciences Research
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Minority Health and Health Disparities
  Office of Disease Prevention
  Office of Research on Women's Health
  Application Receipt Date(s): May 15, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional)
  (RFA-CA-20-027)
  National Cancer Institute
  Application Receipt Date(s): July 31, 2020; July 30, 2021
  
  

• Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R21 Clinical Trial Optional)
  (RFA-CA-20-028)
  National Cancer Institute
  Application Receipt Date(s): July 31, 2020; July 30, 2021
  
  

• Patient-oriented Research to Mitigate Health Disparities and Lessen the Burden of Chronic Diseases Within the Mission of NIDDK (R01 Clinical Trial Optional)
  (RFA-DK-20-015)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): May 22, 2020 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Genomic Predictors of Pregnancy Loss (R01 Clinical Trial Not Allowed)
  (RFA-HD-21-005)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Human Genome Research Institute
  Application Receipt Date(s): July 30, 2020
  
  

• Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)
  (RFA-HG-20-014)
  National Human Genome Research Institute
  Application Receipt Date(s): June 24, 2020; March 9, 2021; February 4, 2022
  
  

• Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed)
  (RFA-HG-20-015)
  National Human Genome Research Institute
  Application Receipt Date(s): June 24, 2020; March 9, 2021; February 4, 2022
  
  

• Novel Synthetic Nucleic Acid Technology Development (R43/R44)( Clinical Trial not allowed)
  (RFA-HG-20-016)
  National Human Genome Research Institute
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): June 24, 2020; March 9, 2021; February 4, 2022 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.